12 recruiting, 9 active not recruiting, 5 terminated, 5 unknown. 39 Phase 2, 15 Phase 1, 1 Phase 3.
Follow DLBCL: new trials by email Literature Review of DLBCL trials Research Report on DLBCL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pirtobrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL pirtobrutinib combined with BEAM - DLBCL | Phase 2 | Not yet recruiting | Ruijin Hospital | 28 | 2026-08-25 | 2026-08-19 |
| Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL EZH2i+GLofit-GemOx - DLBCL | Phase 1 / Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 46 | 2026-06-01 | 2026-06-12 |
| Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma Epcoritamab, Loncastuximab Tesirine - Large B-cell Lymphoma, Relapse | Phase 2 | Recruiting | University of Miami | 26 | 2026-01-07 | 2026-10-15 |
| Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma BAFF-R CAR-T - DLBCL, CLL | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-11-29 | 2026-05-13 |
| Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy Drug therapy - DLBCL, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | First Affiliated Hospital of Ningbo University | 50 | 2025-01-15 | 2025-03-18 |
| CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p) CDR-CHOP - DLBCL | Phase 2 | Not yet recruiting | Ruijin Hospital | 34 | 2024-12-31 | 2024-12-27 |
| CR-CHOP+X in Previously Untreated DEL CR-CHOP+PD1 inhibitor, CR-CHOP + Orelabrutinib, CR-CHOP + decitabine - DLBCL | Phase 2 | Recruiting | Ruijin Hospital | 49 | 2024-12-10 | 2024-12-30 |
| Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL zanubrutinib combined with BEAM, BEAM - DLBCL | Phase 2 | Not yet recruiting | Ruijin Hospital | 66 | 2024-11-01 | 2024-10-22 |
| A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients Trilaciclib+R-CHOP - DLBCL | Phase 2 | Recruiting | Sun Yat-sen University | 38 | 2024-05-23 | 2024-08-26 |
| Study of Oral MRT-2359 in Selected Cancer Patients Oral MRT-2359 - NSCLC, SCLC | Phase 1 / Phase 2 | Active not recruiting | Monte Rosa Therapeutics, Inc | 174 | 2022-10-12 | 2026-11-06 |
| SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression Selinexor combined with Prednisone, Etoposide, and Lenalidomide - DLBCL | Phase 1 / Phase 2 | Unknown | The Affiliated Hospital of Qingdao University | 67 | 2022-10-01 | 2022-08-19 |
| Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS) Tislelizumab, Pemetrexed - DLBCL | Phase 2 | Active not recruiting | Seoul National University Hospital | 28 | 2022-08-18 | 2026-04-24 |
| A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) RNK05047 - Advanced Solid Tumor, DLBCL | Phase 1 / Phase 2 | Recruiting | Ranok Therapeutics (Hangzhou) Co., Ltd. | 32 | 2022-07-12 | 2025-03-04 |
| Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma Orelabrutinib and Gemox - DLBCL | Phase 2 | Unknown | Sun Yat-sen University | 77 | 2022-07-01 | 2022-07-08 |
| Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL Camrelizumab - Primary Extranodal Lymphoma, DLBCL | Phase 2 | Unknown | Sun Yat-sen University | 30 | 2022-06-01 | 2022-04-07 |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) Zilovertamab vedotin, Rituximab, Gemcitabine - DLBCL, Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 290 | 2022-01-14 | 2026-11-03 |
| Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older Tafasitamab, Lenalidomide, Rituximab - DLBCL | Phase 2 | Active not recruiting | The Lymphoma Academic Research Organisation | 71 | 2021-12-20 | 2026-06-04 |
| Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies Ibrutinib Combined With Rituximab - DLBCL, MYD88 Gene Mutation | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 20 | 2021-10-01 | 2021-08-06 |
| A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL Polatuzumab vedotin, Rituximab, Cyclophosphamide - DLBCL, Lymphoma, B-Cell | Phase 2 | Active not recruiting | University of Rochester | 39 | 2021-09-20 | 2026-09-18 |
| Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL Tafasitamab and Lenalidomide - DLBCL | Phase 2 | Recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 50 | 2021-09-06 | 2022-09-23 |
Showing 20 of 39. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (7) · Recurrence (6) · Lymphoma (5) · Lymphoma, Follicular (3) · Lymphoma, Mantle-Cell (3) · Lymphoma, Non-Hodgkin (3) · Breast Neoplasms (2) · Lymphoma, B-Cell, Marginal Zone (2) · Multiple Myeloma (2) · Neoplasms (2) · Small Cell Lung Carcinoma (2) · Carcinoma, Non-Small-Cell Lung (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Head and Neck Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1)
Hemic and Lymphatic Diseases (16) · Immune System Diseases (16) · Immunoproliferative Disorders (16) · Lymphatic Diseases (16) · Lymphoproliferative Disorders (16) · Neoplasms by Histologic Type (16) · Neoplasms (14) · Lymphoma (11) · Lymphoma, Non-Hodgkin (11) · Lymphoma, B-Cell (9) · Disease Attributes (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Hematologic Diseases (3) · Blood Protein Disorders (2)
Rituximab (11) · Cyclophosphamide (8) · Doxorubicin (7) · Prednisone (7) · Vincristine (6) · Lenalidomide (4) · Bendamustine Hydrochloride (2) · Etoposide (2) · Gemcitabine (2) · acalabrutinib (2) · orelabrutinib (2) · tafasitamab (2) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · 90Y-octreotide, DOTA-Tyr(3)- (1) · Brentuximab Vedotin (1)
Ruijin Hospital (4) · Sun Yat-sen University (4) · The Lymphoma Academic Research Organisation (3) · Stichting Hemato-Oncologie voor Volwassenen Nederland (2) · The First Affiliated Hospital with Nanjing Medical University (2) · University of Rochester (2) · Acerta Pharma BV (1) · Autolus Limited (1) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · Chinese Academy of Medical Sciences (1) · Cyteir Therapeutics, Inc. (1) · First Affiliated Hospital of Ningbo University (1) · Fondazione Italiana Linfomi - ETS (1) · Genmab (1) · IGM Biosciences, Inc. (1)
United States (16) · China (12) · France (6) · Italy (5) · Belgium (4) · South Korea (4) · United Kingdom (4) · Australia (3) · Netherlands (3) · Spain (3) · Canada (2) · Denmark (2) · Poland (2) · Argentina (1) · Brazil (1)
Carla Casulo (1) · Christopher Fletcher, MD (1) · Christopher J Melani, M.D. (1) · Emmanuelle Tchernonog (1) · Franck Morshhauser, Pr (1) · Gilles Salles (1) · Huiqiang Huang, professor (1) · Juan Alderuccio, MD (1) · Julien Depaus (1) · Linda Grummer (1) · Loic Ysebaert, MD (1) · M. Nijland, PhD/MD (1)
PMID 30446007, PMID 31724191, PMID 32122924, PMID 32299513, PMID 33750072, PMID 34269152, PMID 34508654, PMID 36548927, PMID 37399456, PMID 38022532, PMID 38151388, PMID 38889737, PMID 39322711, PMID 40249860, PMID 40472301, PMID 40802906, PMID 41176775, PMID 42411504, PMID 42431612, PMID 42541678
2017 (2), 2016 (1), 2023 (1)